South Plainfield, NJ-based Prolong Pharmaceuticals says it snared $30 million in financing from unnamed investors. The company is pursuing new anemia therapies. "As we move toward the clinic with our Sanguinate product we are pleased to receive this level of financing for the next phase of our efforts," said Prolong President Glenn Kazo. "Over the coming months we will be focused on developing sufficient manufacturing capacity to supply our clinical development needs, researching additional indications, and expanding the infrastructure we expect to require as we move forward with Sanguinate." Prolong release